Immunic (NASDAQ:IMUX) Now Covered by Analysts at William Blair

William Blair initiated coverage on shares of Immunic (NASDAQ:IMUX) in a research report report published on Tuesday morning, MarketBeat.com reports. The brokerage issued an outperform rating on the stock.

Other research analysts also recently issued reports about the company. D. Boral Capital reaffirmed a “buy” rating and issued a $17.00 price target on shares of Immunic in a research report on Wednesday, February 26th. StockNews.com downgraded shares of Immunic from a “hold” rating to a “sell” rating in a research note on Thursday, March 20th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Immunic in a research note on Friday, February 21st. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $12.67.

Immunic Stock Performance

Immunic stock opened at $1.25 on Tuesday. Immunic has a 52 week low of $0.92 and a 52 week high of $2.11. The firm has a market capitalization of $112.60 million, a PE ratio of -1.02 and a beta of 1.89. The business’s 50-day simple moving average is $1.07 and its 200-day simple moving average is $1.21.

Institutional Investors Weigh In On Immunic

Several institutional investors and hedge funds have recently bought and sold shares of IMUX. Focus Partners Wealth increased its stake in Immunic by 1.1% in the fourth quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock valued at $2,168,000 after acquiring an additional 23,610 shares during the period. 683 Capital Management LLC boosted its holdings in Immunic by 2.2% during the fourth quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock valued at $700,000 after purchasing an additional 15,349 shares in the last quarter. Millennium Management LLC grew its stake in shares of Immunic by 480.6% in the 4th quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock valued at $580,000 after purchasing an additional 479,846 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Immunic by 45.6% in the 4th quarter. Renaissance Technologies LLC now owns 566,623 shares of the company’s stock worth $567,000 after buying an additional 177,542 shares in the last quarter. Finally, Bridgeway Capital Management LLC raised its holdings in shares of Immunic by 11.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock worth $215,000 after buying an additional 22,200 shares in the last quarter. Institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.